This inventor holds 2 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Mitsubishi Tanabe Pharma Corporation, Osaka University. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2021-2023
Title: Innovations of Shuhei Yamakoshi
Introduction
Shuhei Yamakoshi is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patents. With a total of two patents to his name, Yamakoshi's work focuses on compounds that have the potential to address critical health issues.
Latest Patents
One of Yamakoshi's latest patents is a lysophosphatidic acid derivative. This invention aims to provide a compound that acts as a specific agonist for LPA4 receptors. The pharmaceutical composition containing this compound is designed for the prophylaxis and treatment of diseases associated with angiogenesis abnormalities and vascular disorders. Another significant patent is related to a bridged nucleic acid known as GuNA. This patent outlines a method for producing the compound, which involves a reaction with a reducing agent to cleave an oxazolidine ring.
Career Highlights
Throughout his career, Shuhei Yamakoshi has worked with prominent organizations such as Mitsubishi Tanabe Pharma Corporation and Osaka University. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to advancements in medical science.
Collaborations
Yamakoshi has collaborated with several talented individuals in his field, including Maiko Hamada and Yuki Arai. These collaborations have fostered a creative environment that encourages the development of groundbreaking inventions.
Conclusion
Shuhei Yamakoshi's contributions to the field of pharmaceuticals through his innovative patents highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments and therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile